Lexaria Bioscience (LEXX) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Lexaria Bioscience has received ethics board approval for its 12-week Phase 1b GLP-1 study, which focuses on diabetes and weight loss, marking a significant step towards commencing trials. The company has completed manufacturing of the clinical test articles for all study arms, including various DehydraTECH formulations and a comparator arm. The study is anticipated to begin dosing by late December or January 2025, pending further regulatory approvals.
For further insights into LEXX stock, check out TipRanks’ Stock Analysis page.
